Share via Email


* Email To: (Separate multiple addresses with a semicolon)
* Your Name:
* Email From: (Your IP Address is 54.224.216.155)
* Email Subject: (personalize your message)


Email Content:

Poster presented at 9th international Symposium in Avian Influenza – Athens, GA, USA – April 12-15, 2015.

04/22/2015

CEVA has developed an effective genetically engineered vector vaccine against H5 avian influenza. The product is used commercially in North Africa. Although current Federal policy disallows vaccination, if eradication proves infeasible in the face of extensive spread, the CEVA product will prove valuable in a program to suppress clinical infection.